Virus News and Research

Latest Virus News and Research

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

Influenza surveillance mechanisms in Mexico were adequate during the fast-spreading H1N1 outbreak in 2009, yet Mexico did not have the infrastructure to quickly identify the emergence of this novel strain, according to an Arizona State University (ASU) epidemiologist.

21 Feb 2010

News outlets examine HIV vaccine research, cervical cancer screening data presented at conference

Several news outlets examine the latest reports out of this week's Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

20 Feb 2010

Quidel acquires Diagnostic Hybrids for $130 million

Quidel Corporation, a leading provider of rapid diagnostic tests, has completed its previously announced acquisition of Diagnostic Hybrids, Inc. for approximately $130 million in cash.

20 Feb 2010

GenVec announces new contract with DHS to develop adenovector-based vaccines against FMD

Today GenVec, Inc. announced a new contract with the Department of Homeland Security to continue the development of adenovector-based vaccines against foot-and-mouth disease (FMD) based on research and development done in collaboration with USDA-ARS and DHS S&T scientists at the Plum Island Animal Disease Center.

19 Feb 2010

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Novavax, Inc. today presented to the world's leading pandemic influenza vaccine experts a summary of the recent preliminary safety and immunogenicity data from its Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study in Mexico.

19 Feb 2010

Amerigroup's fourth-quarter revenues rise 18.5%

Amerigroup Corporation today announced that net income for the fourth quarter of 2009 was $40.2 million, or $0.79 per diluted share, versus $35.9 million, or $0.67 per diluted share, for the fourth quarter of 2008. For the year ended December 31, 2009, the Company's net income was $149.3 million, or $2.85 per diluted share.

19 Feb 2010

State policy developments: Wisconsin's new 'public option,' Iowa's medical marijuana vote, and more

New Hampshire Public Radio: A bill in the state legislature would create an annual public report that details the causes of rising health spending by analyzing now-private information that doctors, hospitals and other health organizations would have to provide to the state's Department of Insurance. The move is partly in response to conflicting narratives: The state's health spending continues to rise, yet hospitals and doctors say they are struggling (Grant, 2/17).

19 Feb 2010

Simple molecular kit to reprogram any cell of the body into another

In an effort to sidestep the ethical dilemma involved in using human embryonic stem cells to treat diseases, scientists are developing non-controversial alternatives: In particular, they are looking for drug-like chemical compounds that can transform adult skin cells into the stem cells now obtained from human embryos. That's the topic of a fascinating article in Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

19 Feb 2010

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases such as HIV and cardiovascular diseases, announced results from its prophylactic HIV vaccine (VRX1023) study in Rhesus Macaque monkeys during a presentation today at the 2010 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA.

19 Feb 2010

Researchers develop technology to preserve vaccines in tropical temperatures

A team of British researchers have developed a simple, low-cost method to preserve vaccines in tropical climates, which they say could help to revolutionalize vaccination campaigns in developing countries, Reuters reports.

19 Feb 2010

Gentel Biosciences launches integrated Proteomics Multi-System

Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing “scan-to-analysis” functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.

19 Feb 2010

Walker's book focuses on deaths, genetic deformities and other health issues resulting from environmental pollution

Since the brain-injuring virus needs mosquitoes and pigs to spread, government officials should ban standing water in cemetery cisterns and urban drainage ditches. They should keep industrial "piggeries" away from cities and their populations.

19 Feb 2010

WHO recommends H1N1 be added to next year's seasonal flu virus

The WHO is recommending the H1N1 (swine flu) virus be added to the regular flu vaccine for the Northern Hemisphere's 2010-2011 regular flu season, the Associated Press reports (2/18).

19 Feb 2010

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

18 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.

18 Feb 2010

Viral infection can suppress immune response to secondary bacterial infection

A new study reveals how infection with the influenza virus impacts the way that the immune system responds to subsequent infections. The research, published by Cell Press in the February 18th issue of the journal Cell Host and Microbe, provides a new understanding of the physiological and pathological consequences of the flu.

18 Feb 2010

Gene study could pave way for novel methods for plagues and other infectious diseases

An international consortium of scientists, including Universitat Aut-noma de Barcelona (UAB) researcher Deodoro Oliveira, have sequenced the genome of three species of parasitoid wasps of the genus Nasonia.

18 Feb 2010

Multiple, independent European blood centers to report on INTERCEPT Blood System for platelets and plasma

Cerus Corporation announced today that investigators from blood centers in Sweden, Belgium, France and Slovenia will present their experience with the INTERCEPT Blood System for platelets and plasma during a leading international transfusion safety meeting, the XIIth International Haemovigilance Seminar taking place in Dubrovnik, Croatia from February 17 to 19.

18 Feb 2010

Virus News and Research

Latest Virus News and Research

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

News outlets examine HIV vaccine research, cervical cancer screening data presented at conference

Quidel acquires Diagnostic Hybrids for $130 million

GenVec announces new contract with DHS to develop adenovector-based vaccines against FMD

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Amerigroup's fourth-quarter revenues rise 18.5%

State policy developments: Wisconsin's new 'public option,' Iowa's medical marijuana vote, and more

Simple molecular kit to reprogram any cell of the body into another

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

Researchers develop technology to preserve vaccines in tropical temperatures

Gentel Biosciences launches integrated Proteomics Multi-System

Walker's book focuses on deaths, genetic deformities and other health issues resulting from environmental pollution

WHO recommends H1N1 be added to next year's seasonal flu virus

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

Viral infection can suppress immune response to secondary bacterial infection

Gene study could pave way for novel methods for plagues and other infectious diseases

Multiple, independent European blood centers to report on INTERCEPT Blood System for platelets and plasma

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in